Research Article
Genetic Background of Immune Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children
Table 2
Characteristics of studied groups.
| | Pre-HSCT group | | 33 | | Sex | Boys 25, girls 8 | | Age (years) | 1.5–19 (median 10.5) | | Chemotherapy before HSCT (%) | 23 (71%) | | First line | 13 | | Second line | 9 | | ≥third line | 1 | | Local radiotherapy | 7 | | Cranial (dose) | 5 (12 Gy-4, 18 Gy-1) | | Testes (dose) | 2 (12 Gy/24 Gy, 18 Gy/18 Gy) | | Time since diagnosis and patient selection (years) | Median, 1.4; range 0.08–12.9 |
| | Post-HSCT group | | 20 | | Sex | Boys 14, girls 7 | | Age (years) | 2.8–19.5 (median 9.6) | | Conditioning regimen based on busulfan () | 9 (45%) | | Total body irradiation, 12 Gy/6 fractions () | 6 (30%) | | GvHD prophylaxis () | | | Ciclosporin | 2 (10%) | | Methotrexate + ciclosporin | 18 (90%) | | GvHD () | 14 (70%) | | Median time from HSCT to the second assessment (range) | 6.4 (6–13) months | | Systemic glucocorticoids (%) | 16 (80%) | | Median and range of cumulative dose of glucocorticoids (equivalent of prednisone) | 1463 (29–9758) mg/m2 | | Median duration of systemic glucocorticoids therapy | 105 (3–240) days | | Median time since discontinuation of glucocorticoids (range) | 3.5 (0.4–14.3) months | | Median time from discontinuation of immunosuppressive treatment to the second assessment (range) (16 patients) | 1.8 (0–9) months |
|
|
